MaxCyte Inc reports results for the quarter ended March 31 - Earnings Summary

MaxCyte

08/05/2025 07:40

MaxCyte Inc MXCT.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -9 cents.  The mean expectation of five analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -12 cents to -10 cents per share.

Revenue fell 8.4% to $10.39 million from a year ago; analysts expected $9.68 million.

MaxCyte Inc's reported EPS for the quarter was a loss of 10 cents​.

The company reported a quarterly loss of $10.26 million.

MaxCyte Inc shares had risen by 0.4% this quarter and lost 34.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 3.5% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "strong buy"

Wall Street's median 12-month price target for MaxCyte Inc is $7.00

This summary was machine generated from LSEG data May 8 at 06:39 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.10
-0.10
Met
Dec. 31 2024
-0.12
-0.10
Beat
Sep. 30 2024
-0.12
-0.11
Beat
Jun. 30 2024
-0.13
-0.09
Beat